14 research outputs found
First report of transmission of a highly resistant strain of HIV-1 group O
Groupe de travail dans la liste des auteurs : RES-O Surveillance NetworkInternational audienc
Suspicion of Fenofibrate-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: a Case Report
We describe a DRESS syndrome induced by fenofibrate. This side effect, rarely described
with fenofibrate, should be known by clinicians to stop it immediately and avoid serious
complications
Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial
International audienceLenalidomide, an oral immunomodulating agent, has shown promising activity in HIV-infected individuals with Kaposi's sarcoma (KS). This single-arm, multicenter, open-label, Gehan's two-stage phase II trial evaluated the efficacy and safety of lenalidomide in HIV-infected patients with progressive KS despite previous chemotherapy (NCT01282047, ANRS 154 Lenakap trial). The primary endpoint was the rate of partial response (PR) or complete response (CR) at week 24, evaluated by both the study investigators and the patients using the Physical Global Assessment (PGA). AIDS Clinical Trials Group (ACTG) criteria for KS treatment evaluation were used as a secondary endpoint. The data and safety monitoring board recommended that enrollments be halted on April 24, 2013, because of lack of responses. We enrolled 12 antiretroviral-treated HIV-infected men with progressive KS despite previous chemotherapy. Their HIV plasma viral load was <50 copies/ml and their median CD4 cell count 444/mm3. One patient stopped taking lenalidomide because of hives at week 1 and a second patient died at week 7. The remaining 10 patients were assessable at week 24, when none had PGA-defined CR or PR and one had ACTG-defined PR. There were no additional PGA responses at week 48, but an additional three patients had ACTG responses, for a total of four patients with ACTG PR at week 48 (40%; 95% confidence interval: 12.2–73.8). Fourteen grade 3–4 adverse events were considered at least possibly related to lenalidomide during a total of 101 cycles. Lenalidomide was well tolerated in antiretroviral experienced patients with progressive KS previously treated with chemotherapy. The ACTG-defined response rate at week 48 was 40%, while it was 0% using PGA criteria
Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis
<p><b>(a)</b> Correlogram of baseline virological and immunological markers for 19 patients. Heatmaps and pie charts indicate associations between the variables. Red indicates a positive correlation and blue a negative correlation. The intensity and size of the colored part of pie represent the strength of the association. Spearman correlations were assumed for p values <0.05 between virological markers and immunological markers. <b>(b)</b> Circle of correlations of baseline virological and immunological markers with the first two components from Principal Component Analysis (PCA) (65% of the total variance). Blood and semen HIV-RNA and HIV-DNA are designated as follows: bRNA, bDNA, sRNA, sDNA.</p
Changes in seminal and blood HIV-RNA and HIV-DNA between D0 (cART initiation during PHI) and M24 (2 years of cART).
<p>As shown on the right panel, an increase in seminal HIV-DNA load with stable blood HIV-DNA load occurred in two patients. Horizontal lines are the detection thresholds.</p
HIV-RNA and HIV-DNA load and HIV-RNA/HIV-DNA ratio during PHI before cART initiation, in blood and semen, in patients with acute infection (n = 8, black dots) and recent infection (n = 11, triangles).
<p>HIV-RNA and HIV-DNA load and HIV-RNA/HIV-DNA ratio during PHI before cART initiation, in blood and semen, in patients with acute infection (n = 8, black dots) and recent infection (n = 11, triangles).</p
Correlations between seminal HIV-RNA and (a) blood HIV-RNA, (b) the CD4 cell count, and (c) the CD4/CD8 ratio, and between IP-10 and (d) blood HIV-RNA (e) seminal HIV-DNA, and (f) blood HIV-DNA, according to primary infection status: Acute infection (black dots), and recent infection (triangles).
<p>Correlations between seminal HIV-RNA and (a) blood HIV-RNA, (b) the CD4 cell count, and (c) the CD4/CD8 ratio, and between IP-10 and (d) blood HIV-RNA (e) seminal HIV-DNA, and (f) blood HIV-DNA, according to primary infection status: Acute infection (black dots), and recent infection (triangles).</p
Demographic and baseline characteristics.
<p>Data are number (%) or median (min-max). MSM = men who have sex with men. PBMC = peripheral blood mononuclear cells. Acute HIV infection was defined by the presence of one band or fewer on HIV-1 western blot, plus detectable plasma HIV-RNA. P values: acute vs recent infection (Wilcoxon Exact test).</p